Loading patent…
AssigneeSyntis Bio, Inc.
InventorsKierra Aleece FRANKLIN, Stephanie Sue GALANIE, Gjalt W. HUISMAN, Nikki D. KRUSE, Kerryn MCCLUSKIE, Vesna MITCHELL, Leann Quertinmont TEADT, Kristen Jean VALLIEU
Estimating the term…
The present invention provides engineered methionine gamma lyase polypeptides and compositions thereof. The engineered methionine gamma lyase polypeptides have been optimized to provide improved thermostability, protease stability, and stability under a range of pH conditions, including acidic (pH<7) conditions. The present invention also relates to the use of the compositions comprising the engineered methionine gamma lyase polypeptides for therapeutic purposes.
1-58. (canceled)
A method for treating and/or preventing the symptoms of homocystinuria in a subject, comprising administering to a subject having homocystinuria an effective amount of a recombinant methionine gamma lyase comprising a polypeptide sequence comprising at least 70% sequence identity to a reference sequence of SEQ ID NO:
63-67. (canceled)
(canceled)
Dependencies are inferred from the claim text.